GILEAD SCIENCES, INC. Contract with Customer, Refund Liability, Current
GILEAD SCIENCES, INC. (GILD) had Contract with Customer, Refund Liability, Current of $321.00 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Revenue from Contract with Customer
us-gaap:ContractWithCustomerRefundLiabilityCurrent · last filed 2026-02-24
- 2025-12-31: Contract with Customer, Refund Liability, Current $321.00M.
- 2024-12-31: Contract with Customer, Refund Liability, Current $321.00M.
- 2024-09-30: Contract with Customer, Refund Liability, Current $321.00M.
- 2024-06-30: Contract with Customer, Refund Liability, Current $413.00M.
| Period end | Contract with Customer, Refund Liability, Current |
|---|---|
| 2025-12-31 | $321.00M 10-K · filed 2026-02-24 |
| 2024-12-31 | $321.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $321.00M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $413.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $376.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $387.00M 10-K · filed 2025-02-28 |
| 2023-09-30 | $403.00M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $438.00M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $444.00M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $422.00M 10-K · filed 2024-02-23 |
| 2022-09-30 | $392.00M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $381.00M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $403.00M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $499.00M 10-K · filed 2023-02-22 |
| 2021-09-30 | $530.00M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $532.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $524.00M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $587.00M 10-K · filed 2022-02-23 |
| 2019-12-31 | $137.00M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |